Every material Form 8-K Turn Therapeutics Inc. has filed with the SEC since September 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Turn Therapeutics reported a third-quarter 2026 net loss of $6.2 million, or $(0.21) per share, up from $1.9 million, or $(0.07) per share, a year earlier. The company said its $10.4 million in cash as of September 30, 2026 is expected to fund operations into the third quarter of 2027, which matters to shareholders given the higher loss and the need for further capital.
Q3 2026 net loss was $6.2 million, or $(0.21) per basic and diluted share, versus $1.9 million, or $(0.07), in Q3 2025
Net loss from change in fair value of derivative liability instrument was $3.3 million in the quarter, compared with none in the prior-year period
Cash and cash equivalents were $10.4 million at September 30, 2026, with operations expected to be funded into the third quarter of 2027
Turn Therapeutics furnished an updated investor presentation dated October 6, 2026, as Exhibit 99.1 to a Regulation FD 8-K. The deck lays out the GX-03 pipeline, with a Phase 2 topline readout in atopic dermatitis expected in Q1 2027 and cash runway into Q3 2027, and it reports no new financial results.
Cash balance of $10.3 million as of June 30, 2026, with cash runway into Q3 2027
Stage 2 atopic dermatitis trial is currently enrolling about 135 patients; topline results expected Q1 2027
Phase 3 atopic dermatitis initiation planned for mid-2027; FDA Type B meeting planned for Q4 2026
About 29.8 million common shares outstanding as of June 30, 2026
Turn Therapeutics announced that its CEO Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn, M.D., will present at the Stifel 2026 Virtual Immunology and Inflammation Forum. The presentation covers the atopic dermatitis clinical program, including a pruritus-focused stage 2 enrichment strategy. The filing is a routine investor event notice and contains no financial results or guidance.
Presentation scheduled for September 23, 2026 at 1:30 PM ET
Presenters: Bradley Burnam, CEO, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead
Topics include the stage 2 enrichment strategy and patient populations with moderate-severe baseline pruritus and lower EASI scores
Live webcast and replay available on the Turn Therapeutics investor website
Turn Therapeutics appointed Robert R. Redfield, M.D., former Director of the U.S. Centers for Disease Control and Prevention, as Chief Scientific Officer. The filing says he will contribute to the scientific and clinical strategy for GX-03 across several indications.
Robert R. Redfield, M.D., appointed Chief Scientific Officer, announced September 9, 2026
Redfield served as the 18th Director of the U.S. Centers for Disease Control and Prevention, from 2018 to 2021
GX-03 is being evaluated in atopic dermatitis and developed for onychomycosis, hidradenitis suppurativa, and potential additional indications
Stephen M. Hahn, M.D., former FDA Commissioner, is listed as Executive Clinical and Regulatory Lead
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Turn Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →